Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Apple Turns 50: From Garage Startup to AI Crossroads 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Britain Courts Anthropic Amid US Defense Department Dispute 
EMERYVILLE, Calif., Nov. 22, 2016 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Gail Farfel, Ph.D., Chief Development Officer, will participate in the Oppenheimer Life Sciences Summit 2016, being held at the Sofitel New York Hotel on Tuesday, November 29th.
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | [email protected]
